臨床外科67巻11号

2012年10月発行

特集 外科医のための癌診療データ

臓器別最新データ 5．胃癌

胃癌の非切除・再発例

著者： 田中浩明¹ 六車一哉¹ 櫻井克宣¹ 久保尚士¹ 山本篤¹ 山下好人¹ 澤田鉄二¹ 大平雅一¹ 平川弘聖¹

所属機関： ¹大阪市立大学大学院医学研究科腫瘍外科学

ページ範囲：P.132 - P.137

文献概要

覚えておきたいデータ

◆非切除胃癌に対する治療は化学療法が中心で現在はS-1＋シスプラチン療法が標準治療であり，奏効率は54％，全生存期間中央値は13か月である．

◆無症状再発症例の予後は良好であり，CTを用いた術後サーベイランスが重要である．再発率は30％であり，腹膜播種再発が最も多い．

◆再発後の治療は，分子標的薬を含めた集学的治療の効果を検証する臨床試験の結果が待たれる．

参考文献

1）Boku N, Yamamoto S, Fukuda H, et al：Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer：a randomised phase 3 study. Lancet Oncol 10：1063-1069, 2009

2）Koizumi W, Narahara H, Hara T, et al：S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer（SPIRITS trial）：a phase Ⅲ trial. Lancet Oncol 9：215-221, 2008

3）Narahara H, Iishi H, Imamura H, et al：Randomized phase Ⅲ study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer（study GC0301/TOP-002）. Gastric Cancer 14：72-80, 2011

4）Fujii M, Kim YH. Satoh T, et al：Randomized phase Ⅲ study of S-1 alone versus S-1 plus docetaxel（DOC）in the treatment for advanced gastric cancer（AGC）：The START trial update. J Clin Oncol 29（suppl）：4016, 2011

5）Koizumi W, Takiuchi H, Yamada Y, et al：Phase Ⅱ study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer（G-SOX study）. Ann Oncol 21：1001-1005, 2010

6）Kang YK, Kang WK, Shin DB, et al：Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer：a randomised phase Ⅲ noninferiority trial. Ann Oncol 20：666-673, 2009

7）Ajani JA, Rodriguez W, Bodoky G, et al：Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study：the FLAGS trial. J Clin Oncol 28：1547-1553, 2010

8）Cunningham D, Starling N, Rao S, et al：Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358：36-46, 2008

9）Van Cutsem E, Moiseyenko VM, Tjulandin S, et al：Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer：a report of the V325 Study Group. J Clin Oncol 24：4991-4997, 2006

10）Thuss-Patience PC, Kretzschmar A, Bichev D, et al：Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer―a randomised phase Ⅲ study of the Arbeitsgemeinschaft Internistische Onkologie（AIO）. Eur J Cancer 47：2306-2314, 2011

11）Hamaguchi T, Shirao K, Ohtsu A, et al：A phase Ⅱ study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer：a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group（JCOG0109-DI Trial）. Gastric Cancer 14：226-233, 2011

12）Bang YJ, Van Cutsem E, Feyereislova A, et al：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3, open-label, randomised controlled trial. Lancet 376：687-697, 2010

13）Ohtsu A, Shah MA, Van Cutsem E, et al：Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer：a randomized, double-blind, placebo-controlled phase Ⅲ study. J Clin Oncol 29：3968-3976, 2011

14）Okines AF, Ashley SE, Cunningham D, et al：Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer：dose-finding study for the prospective multicenter, randomized, phase Ⅱ/Ⅲ REAL-3 trial. J Clin Oncol 28：3945-3950, 2010

15）Doi T, Muro K, Boku N, et al：Multicenter phase Ⅱ study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 28：1904-1910, 2010

16）Lee J, Lim do H, Kim S, et al：Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection：the ARTIST trial. J Clin Oncol 30：268-273, 2012

17）Sasako M, Sano T, Yamamoto S, et al：D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359：453-462, 2008

18）Kurokawa Y, Sasako M, Sano T, et al：Functional outcomes after extended surgery for gastric cancer. Br J Surg 98：239-245, 2011

19）Roviello F, Pedrazzani C, Marrelli D, et al：Super-extended（D3）lymphadenectomy in advanced gastric cancer. Eur J Surg Oncol 36：439-446, 2010

20）Tokunaga M, Ohyama S, Hiki N, et al：Can superextended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol 17：2031-2036, 2010

21）Park IH, Kim SY, Kim YW, et al：Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement. Cancer Chemother Pharmacol 67：127-136, 2011

22）Yoshikawa T, Sasako M, Yamamoto S, et al：Phase Ⅱ study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 96：1015-1022, 2009

23）Oyama K, Fushida S, Kinoshita J, et al：Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1（DCS therapy）and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes. J Surg Oncol 105：535-541, 2012

24）Isobe Y, Nashimoto A, Akazawa K, et al：Gastric cancer treatment in Japan：2008 annual report of the JGCA nationwide registry. Gastric Cancer 14：301-316, 2011

25）Yamao T, Shimada Y, Shirao K, et al：Phase Ⅱ study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites：a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol 34：316-322, 2004

26）Imamoto H, Oba K, Sakamoto J, et al：Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions：a multicenter phase Ⅱ trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer 14：81-90, 2011

27）Takiuchi H, Fukuda H, Boku, N, et al：Randomized phase Ⅱ study of best-available 5-fluorouracil（5-FU）versus weekly paclitaxel in gastric cancer（GC）with peritoneal metastasis（PM）refractory to 5-FU containing regimens（JCOG0407）. J Clin Oncol 28（suppl）：4052, 2010

28）Ishigami H, Kitayama J, Kaisaki S, et al：Phase Ⅱ study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 21：67-70, 2010

29）Kodera Y, Imano M, Yoshikawa T, et al：A randomized phase Ⅱ trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis（INPACT trial）. Jpn J Clin Oncol 41：283-286, 2011

30）Fujiwara Y, Takiguchi S, Nakajima K, et al：Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol 105：38-42, 2012

31）Lee SD, Ryu KW, Eom BW, et al：Prognostic significance of peritoneal washing cytology in patients with gastric cancer. Br J Surg 99：397-403, 2012

32）Kodera Y, Ito S, Mochizuki Y, et al：Long-term follow up of patients who were positive for peritoneal lavage cytology：final report from the CCOG0301 study. Gastric Cancer, 2012[Epub ahead of print]

33）Saito H, Kihara K, Kuroda H, et al：Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, but no macroscopic peritoneal metastasis. J Surg Oncol 104：534-537, 2011

34）Dittmar Y, Altendorf-Hofmann A, Rauchfuss F, et al：Resection of liver metastases is beneficial in patients with gastric cancer：report on 15 cases and review of literature. Gastric Cancer 15：131-136, 2012

35）Park HS, Rha SY, Kim HS, et al：A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. Oncology 80：142-150, 2011

36）Go PH, Klaassen Z, Meadows MC, et al：Gastrointestinal cancer and brain metastasis：a rare and ominous sign. Cancer 117：3630-3640, 2011

37）Fujitani K, Yang HK, Kurokawa Y, et al：Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor：Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol 38：504-506, 2008

38）Kerkar SP, Kemp CD, Duffy A, et al：The GYMSSA trial：a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials 10：121, 2009

39）Cardoso R, Coburn NG, Seevaratnam R, et al：A systematic review of patient surveillance after curative gastrectomy for gastric cancer：a brief review. Gastric Cancer, 2012[Epub ahead of print]

40）Kim JH, Jang YJ, Park SS, et al：Benefit of post-operative surveillance for recurrence after curative resection for gastric cancer. J Gastrointest Surg 14：969-976, 2010

41）Sasako M, Sakuramoto S, Katai H, et al：Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer. J Clin Oncol 29：4387-4393, 2011

42）Aoyama T, Yoshikawa T, Hayashi T, et al：Risk Factors for Peritoneal Recurrence in Stage Ⅱ/Ⅲ Gastric Cancer Patients Who Received S-1 Adjuvant Chemotherapy After D2 Gastrectomy. Ann Surg Oncol 19：1568-1574, 2012

43）Shitara K, Morita S, Fujitani K, et al：Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1：multi-institutional retrospective analysis. Gastric Cancer, 2011[Epub ahead of print]

44）Kang HJ, Chang HM, Kim TW, et al：Phase Ⅱ study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer 92：246-251, 2005